CN104945395B - 二氢嘧啶类化合物及其在药物中的应用 - Google Patents
二氢嘧啶类化合物及其在药物中的应用 Download PDFInfo
- Publication number
- CN104945395B CN104945395B CN201510141969.5A CN201510141969A CN104945395B CN 104945395 B CN104945395 B CN 104945395B CN 201510141969 A CN201510141969 A CN 201510141969A CN 104945395 B CN104945395 B CN 104945395B
- Authority
- CN
- China
- Prior art keywords
- compound
- methyl
- thiazol
- synthesis
- morpholin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Bc1cc(F)ccc1[C@@]1N=C(c2ncc[s]2)NC(CN2CC(CCC(O)=O)OCC2)=C1C(OC)=* Chemical compound Bc1cc(F)ccc1[C@@]1N=C(c2ncc[s]2)NC(CN2CC(CCC(O)=O)OCC2)=C1C(OC)=* 0.000 description 26
- YMUWWZRASYKWQY-VFNWGFHPSA-N CC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O Chemical compound CC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O YMUWWZRASYKWQY-VFNWGFHPSA-N 0.000 description 1
- ZDXVLPOPYFWHAP-QMMMGPOBSA-N CC(CC[C@@H]1NCCOC1)=O Chemical compound CC(CC[C@@H]1NCCOC1)=O ZDXVLPOPYFWHAP-QMMMGPOBSA-N 0.000 description 1
- NYDCUGHAYWYXML-VFYCCFAGSA-N CCOC(C1=C(CN(CCOC2)/C2=C/CC(O)=O)NC(c2ncc[s]2)=N[C@@H]1c(c(Br)c1)ccc1F)=[U] Chemical compound CCOC(C1=C(CN(CCOC2)/C2=C/CC(O)=O)NC(c2ncc[s]2)=N[C@@H]1c(c(Br)c1)ccc1F)=[U] NYDCUGHAYWYXML-VFYCCFAGSA-N 0.000 description 1
- DJFWONZOWWUNRA-PEJQNEDZSA-N CCOC(C1=C(CN2CC(CC(C)(C)C(O)=O)OCC2)NC(c2ncc[s]2)=NC1[C@H](C)c(c(C)c1)ccc1[I]=C)=O Chemical compound CCOC(C1=C(CN2CC(CC(C)(C)C(O)=O)OCC2)NC(c2ncc[s]2)=NC1[C@H](C)c(c(C)c1)ccc1[I]=C)=O DJFWONZOWWUNRA-PEJQNEDZSA-N 0.000 description 1
- KLOOZMZSXQVPOP-KUXBLMNESA-N CCOC(C1=C(CN2CC(CC(C)(C)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(C1CCC1)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2CC(CC(C)(C)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(C1CCC1)c1)ccc1F)=O KLOOZMZSXQVPOP-KUXBLMNESA-N 0.000 description 1
- AWQQRHKGJGKHPZ-TUUUUVLKSA-N CCOC(C1=C(CN2C[C@@H](CCCC(C)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2C[C@@H](CCCC(C)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O AWQQRHKGJGKHPZ-TUUUUVLKSA-N 0.000 description 1
- IWJQEPHIFKEPTF-BTYIYWSLSA-N CCOC(C1=C(CN2C[C@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2C[C@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O IWJQEPHIFKEPTF-BTYIYWSLSA-N 0.000 description 1
- CZVDQFYWJLGGKP-BRNPAFAOSA-N CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)COCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1Cl)=O Chemical compound CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)COCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1Cl)=O CZVDQFYWJLGGKP-BRNPAFAOSA-N 0.000 description 1
- DGHQAPJBSVUVGF-BRNPAFAOSA-N CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)CSCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O Chemical compound CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)CSCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O DGHQAPJBSVUVGF-BRNPAFAOSA-N 0.000 description 1
- GZMVSOUMZTVQQX-FGKVNXAVSA-N CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Cl)=O Chemical compound CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Cl)=O GZMVSOUMZTVQQX-FGKVNXAVSA-N 0.000 description 1
- JRSOYUHCIKHPFU-XCQZSARTSA-N CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)[C@@H](C)OCC2)NC(c2ncc[s]2)=C[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)[C@@H](C)OCC2)NC(c2ncc[s]2)=C[C@H]1c(c(Cl)c1)ccc1F)=O JRSOYUHCIKHPFU-XCQZSARTSA-N 0.000 description 1
- JCMNLGGCPCDXEQ-FGCOXFRFSA-N CCOC(C1=C(CN2[C@H](CCC(O)=O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1Cl)=O Chemical compound CCOC(C1=C(CN2[C@H](CCC(O)=O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1Cl)=O JCMNLGGCPCDXEQ-FGCOXFRFSA-N 0.000 description 1
- UFIPRQDAKPUFRJ-HOQXQUDTSA-N CCOC(C1=C(CN2[C@H](CCC3OC3O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2[C@H](CCC3OC3O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O UFIPRQDAKPUFRJ-HOQXQUDTSA-N 0.000 description 1
- HLWIPUZHQKJFID-ZZZCEONXSA-N CCOC(C1=C(CN2[C@H]([C@H](C)CC(O)=O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@]1(C)c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2[C@H]([C@H](C)CC(O)=O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@]1(C)c(c(Br)c1)ccc1F)=O HLWIPUZHQKJFID-ZZZCEONXSA-N 0.000 description 1
- QMHPIVXBAMUETA-OSPHWJPCSA-N CCOC(CC1=C(CN2C[C@@H](CCC(CC(O)=O)(F)F)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=N Chemical compound CCOC(CC1=C(CN2C[C@@H](CCC(CC(O)=O)(F)F)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=N QMHPIVXBAMUETA-OSPHWJPCSA-N 0.000 description 1
- MYXIBPRZMDKZRH-PJFKCVFWSA-N CCOCC(C1=C(CN2C[C@@H](CCC(C)=O)OCC2)NC(c2ncc[s]2)=NC1C/C=C\C(\Cl)=C/C(C)Cl)=O Chemical compound CCOCC(C1=C(CN2C[C@@H](CCC(C)=O)OCC2)NC(c2ncc[s]2)=NC1C/C=C\C(\Cl)=C/C(C)Cl)=O MYXIBPRZMDKZRH-PJFKCVFWSA-N 0.000 description 1
- QOBYCXCWVMTCSB-PEGVVKOVSA-N COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1C1C=CC(F)=CC1CCl)=O Chemical compound COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1C1C=CC(F)=CC1CCl)=O QOBYCXCWVMTCSB-PEGVVKOVSA-N 0.000 description 1
- BWVKMHFWCULXRS-VLIAUNLRSA-N COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c1ccccc1Cl)=O Chemical compound COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c1ccccc1Cl)=O BWVKMHFWCULXRS-VLIAUNLRSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510141969.5A CN104945395B (zh) | 2014-03-28 | 2015-03-27 | 二氢嘧啶类化合物及其在药物中的应用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014101262020 | 2014-03-28 | ||
| CN201410126202 | 2014-03-28 | ||
| CN201410596489 | 2014-10-29 | ||
| CN2014105964893 | 2014-10-29 | ||
| CN201510141969.5A CN104945395B (zh) | 2014-03-28 | 2015-03-27 | 二氢嘧啶类化合物及其在药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104945395A CN104945395A (zh) | 2015-09-30 |
| CN104945395B true CN104945395B (zh) | 2018-01-23 |
Family
ID=54160517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510141969.5A Active CN104945395B (zh) | 2014-03-28 | 2015-03-27 | 二氢嘧啶类化合物及其在药物中的应用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9771358B2 (https=) |
| EP (1) | EP3122747B1 (https=) |
| JP (1) | JP2017512789A (https=) |
| KR (1) | KR20160133563A (https=) |
| CN (1) | CN104945395B (https=) |
| AU (1) | AU2015236982B2 (https=) |
| CA (1) | CA2938050A1 (https=) |
| MX (1) | MX2016012573A (https=) |
| MY (1) | MY196243A (https=) |
| RU (1) | RU2682672C2 (https=) |
| SG (1) | SG11201605896WA (https=) |
| WO (1) | WO2015144093A1 (https=) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013096744A1 (en) | 2011-12-21 | 2013-06-27 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
| EA038942B1 (ru) | 2012-08-28 | 2021-11-12 | Янссен Сайенсиз Айрлэнд Юси | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b |
| HUE034820T2 (en) | 2013-02-28 | 2018-02-28 | Janssen Sciences Ireland Uc | Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B |
| EA027068B1 (ru) | 2013-04-03 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b |
| EA035500B1 (ru) | 2013-05-17 | 2020-06-25 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b |
| TWI651300B (zh) | 2013-05-17 | 2019-02-21 | 健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| DK3024819T3 (en) | 2013-07-25 | 2018-06-06 | Janssen Sciences Ireland Uc | GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B |
| KR102290189B1 (ko) | 2013-10-23 | 2021-08-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도 |
| SG11201601813UA (en) | 2013-11-27 | 2016-04-28 | Sunshine Lake Pharma Co Ltd | Processes for preparing dihydropyrimidine derivatives and intermediates thereof |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| JP6553059B2 (ja) | 2014-02-05 | 2019-07-31 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｈｂｖ感染の治療のための併用療法 |
| WO2015118057A1 (en) | 2014-02-06 | 2015-08-13 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| EP3271019A1 (en) | 2015-03-19 | 2018-01-24 | Novira Therapeutics Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US10179131B2 (en) * | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| HK1259410A1 (zh) | 2015-09-29 | 2019-11-29 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
| WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| JP6904970B2 (ja) | 2016-03-07 | 2021-07-21 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｂ型肝炎抗ウイルス剤 |
| SG10202011827YA (en) | 2016-04-15 | 2021-01-28 | Novira Therapeutics Inc | Combinations and methods comprising a capsid assembly inhibitor |
| WO2017198201A1 (en) * | 2016-05-19 | 2017-11-23 | Sunshine Lake Pharma Co., Ltd. | Crystalline form, salt and complex of dihydropyrimidine derivative, and uses thereof in medicine |
| CN109843296A (zh) | 2016-06-10 | 2019-06-04 | 英安塔制药有限公司 | 乙型肝炎抗病毒药剂 |
| CN107674072B (zh) * | 2016-08-01 | 2020-11-24 | 广东东阳光药业有限公司 | 二氢嘧啶衍生物及其酸加成物的制备方法 |
| SG10202010180YA (en) | 2016-11-18 | 2020-11-27 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Dihydropyrimidine compound and preparation method and use thereof |
| US11166954B2 (en) | 2016-11-18 | 2021-11-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Dihydropyrimidine compound and preparation method and use thereof |
| CN109111451B (zh) * | 2017-06-26 | 2020-08-11 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| KR20200020887A (ko) | 2017-06-27 | 2020-02-26 | 얀센 파마슈티카 엔.브이. | 헤테로아릴디히드로피리미딘 유도체 및 b형 간염 감염의 치료 방법 |
| US10952978B2 (en) | 2017-08-28 | 2021-03-23 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| JP2021501764A (ja) | 2017-11-02 | 2021-01-21 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Ｂ型肝炎ウイルス（ｈｂｖ）に対して有効な新規高活性アミノチアゾール置換インドール−２−カルボキサミド |
| MA50520A (fr) | 2017-11-02 | 2020-09-09 | Aicuris Gmbh & Co Kg | Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb) |
| TW201927789A (zh) | 2017-12-06 | 2019-07-16 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| TW201936192A (zh) | 2017-12-06 | 2019-09-16 | 美商因那塔製藥公司 | B 型肝炎抗病毒試劑 |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| CA3090125A1 (en) | 2018-03-14 | 2019-09-19 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
| WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CN108329308B (zh) * | 2018-05-16 | 2022-11-01 | 四川科伦博泰生物医药股份有限公司 | 一种二氢嘧啶类化合物的固体形式及其制备方法 |
| CN109021015B (zh) * | 2018-07-12 | 2019-12-03 | 山东大学 | 二氢嘧啶-磷酰胺类衍生物及其制备方法与应用 |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| UY38383A (es) | 2018-09-21 | 2020-04-30 | Enanta Pharm Inc | Heterociclos funcionalizados como agentes antivirales |
| AR117189A1 (es) | 2018-11-02 | 2021-07-21 | Aicuris Gmbh & Co Kg | Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb) |
| UY38435A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) |
| PY1991608A (es) | 2018-11-02 | 2022-02-10 | Aicuris Gmbh & Co Kg | Nueva urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazina activas contra el virus de la hepatitis b (vhb) |
| AR116946A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) |
| PY1991603A (es) | 2018-11-02 | 2020-09-17 | Aicuris Gmbh & Co Kg | Nueva 6,7-dihidro-4h-pirazolo [1,5-a] pirazina indole -2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| AU2019373679A1 (en) | 2018-11-02 | 2021-05-27 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4H-thiazolo(5,4-c)pyridines active against the hepatitis B virus (HBV) |
| US11198693B2 (en) | 2018-11-21 | 2021-12-14 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| TW202035412A (zh) * | 2018-12-20 | 2020-10-01 | 比利時商健生藥品公司 | 雜芳基二氫嘧啶衍生物和治療ｂ型肝炎感染之方法 |
| MX2021010145A (es) | 2019-02-22 | 2021-09-14 | Janssen Sciences Ireland Unlimited Co | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. |
| SG11202111236UA (en) | 2019-04-30 | 2021-11-29 | Aicuris Gmbh & Co Kg | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) |
| SG11202111493WA (en) | 2019-04-30 | 2021-11-29 | Aicuris Gmbh & Co Kg | Novel oxalyl piperazines active against the hepatitis b virus (hbv) |
| PH12021552733A1 (en) | 2019-04-30 | 2023-01-16 | Aicuris Gmbh & Co Kg | Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv) |
| PH12021552749A1 (en) | 2019-04-30 | 2022-07-11 | Aicuris Gmbh & Co Kg | Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv) |
| MA55879A (fr) | 2019-05-06 | 2022-03-16 | Janssen Sciences Ireland Unlimited Co | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CA3140690A1 (en) * | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| CN110615797A (zh) * | 2019-10-11 | 2019-12-27 | 李丽丽 | 用于治疗乙型肝炎的化合物及其用途 |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN116745291A (zh) | 2020-12-17 | 2023-09-12 | 阿斯利康(瑞典)有限公司 | N-(2-(4-氰基噻唑烷-3-基)-2-氧代乙基)-喹啉-4-甲酰胺 |
| EP4289842A4 (en) | 2021-02-05 | 2025-01-08 | Hepagene Therapeutics (HK) Limited | Phenyldihydropyrimidine compound and use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101328171A (zh) * | 2007-06-18 | 2008-12-24 | 张中能 | 一种溴苯基-取代的噻唑二氢嘧啶 |
| CN103626752A (zh) * | 2012-08-24 | 2014-03-12 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61271278A (ja) | 1985-05-20 | 1986-12-01 | イ− ア−ル スクイブ アンド サンズ インコ−ポレ−テツド | ２−置換チオまたはオキソ−４−アリ−ルまたはヘテロシクロ−５−カルボキシ−１，４−ジヒドロピリミジン |
| GB8906168D0 (en) | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
| SE9702563D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | Compounds |
| SE9702564D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | New compounds |
| DE19817262A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue 2-heterocyclisch substituierte Dihydropyrimidine |
| DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| DE19817265A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe |
| AU4289100A (en) | 1999-03-25 | 2000-10-16 | Bayer Aktiengesellschaft | Dihydropyrimidines and their use in the treatment of hepatitis |
| DE10012549A1 (de) | 2000-03-15 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012824A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012823A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013126A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013125A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| WO2005007124A2 (en) | 2003-07-23 | 2005-01-27 | Bristol-Myers Squibb Company | Substituted dihydropyrimidine inhibitors of calcium channel function |
| CN101104617B (zh) | 2006-07-10 | 2010-06-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101104604B (zh) | 2006-07-10 | 2011-03-02 | 北京摩力克科技有限公司 | 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101225084A (zh) | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101328170B (zh) | 2007-06-18 | 2011-09-14 | 张中能 | 一种氟苯基-取代噻唑二氢嘧啶 |
| WO2008154820A1 (fr) | 2007-06-18 | 2008-12-24 | Zhang, Zhongneng | Thiazolyl-dihydropyrimidines à substitution carbéthoxy |
| WO2008154819A1 (fr) | 2007-06-18 | 2008-12-24 | Zhang, Zhongneng | Thiazolyl-dihydropyrimidines à substitution carbéthoxy |
| WO2010069147A1 (zh) | 2008-12-17 | 2010-06-24 | 张中能 | 二氢嘧啶类化合物、其组合物及其应用 |
| CN101744823B (zh) | 2008-12-17 | 2013-06-19 | 广东东阳光药业有限公司 | 一种二氢嘧啶类化合物的固体分散体及其药用制剂 |
| CN101575318B (zh) | 2009-06-25 | 2012-02-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途 |
| WO2013019967A1 (en) | 2011-08-02 | 2013-02-07 | Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California | Modulators of virus assembly as antiviral agents |
| EA026977B1 (ru) | 2012-01-06 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b |
| US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| CN103664897B (zh) | 2012-09-01 | 2018-04-03 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| CN103664925B (zh) | 2012-09-07 | 2018-01-23 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| MX2015002954A (es) * | 2012-09-10 | 2015-06-05 | Hoffmann La Roche | Nuevas 6-aminoacido-heteroarilhidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b. |
| CN103664899B (zh) | 2012-09-11 | 2017-06-16 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| CA2889892A1 (en) | 2012-11-09 | 2014-05-15 | Indiana University Research And Technology Corporation | Alternative uses for hbv assembly effectors |
| MX2015013363A (es) | 2013-03-20 | 2016-01-08 | Univ Indiana Res & Tech Corp | Heteroarildihidropirimidina (hap) fluorescente: tinte de diagnostico para nucleos de virus de la hep b (hbv) en celulas. |
| CN105209470B (zh) | 2013-05-17 | 2018-02-06 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的6‑桥连的杂芳基二氢嘧啶 |
| CN104650069B (zh) | 2013-11-19 | 2019-04-19 | 广东东阳光药业有限公司 | 4-甲基二氢嘧啶类化合物及其在药物中的应用 |
| RU2678990C1 (ru) | 2013-11-19 | 2019-02-05 | Саншайн Лейк Фарма Ко., Лтд. | Соединения дигидропиримидина и их применение в фармацевтических препаратах |
| CN104650070B (zh) | 2013-11-25 | 2018-09-14 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| SG11201601813UA (en) * | 2013-11-27 | 2016-04-28 | Sunshine Lake Pharma Co Ltd | Processes for preparing dihydropyrimidine derivatives and intermediates thereof |
| JP6306750B2 (ja) | 2014-03-07 | 2018-04-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス感染症の治療および予防のための新規な６−縮合ヘテロアリールジヒドロピリミジン |
| BR112016028000B1 (pt) | 2014-05-30 | 2022-05-17 | Qilu Pharmaceutical Co., Ltd | Derivado de alça de di-hidropirimido como um inibidor de hbv |
-
2015
- 2015-03-27 SG SG11201605896WA patent/SG11201605896WA/en unknown
- 2015-03-27 JP JP2016558407A patent/JP2017512789A/ja active Pending
- 2015-03-27 WO PCT/CN2015/075299 patent/WO2015144093A1/en not_active Ceased
- 2015-03-27 US US15/116,226 patent/US9771358B2/en active Active
- 2015-03-27 CA CA2938050A patent/CA2938050A1/en not_active Abandoned
- 2015-03-27 RU RU2016138735A patent/RU2682672C2/ru active
- 2015-03-27 MY MYPI2016702906A patent/MY196243A/en unknown
- 2015-03-27 MX MX2016012573A patent/MX2016012573A/es unknown
- 2015-03-27 EP EP15769748.3A patent/EP3122747B1/en active Active
- 2015-03-27 KR KR1020167029448A patent/KR20160133563A/ko not_active Withdrawn
- 2015-03-27 AU AU2015236982A patent/AU2015236982B2/en active Active
- 2015-03-27 CN CN201510141969.5A patent/CN104945395B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101328171A (zh) * | 2007-06-18 | 2008-12-24 | 张中能 | 一种溴苯基-取代的噻唑二氢嘧啶 |
| CN103626752A (zh) * | 2012-08-24 | 2014-03-12 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
Non-Patent Citations (1)
| Title |
|---|
| 以乙肝病毒核衣壳为靶标的二氢嘧啶类化合物及其作用机制研究进展.;杨秀岩等，;《中国药物化学杂志》;20131231;第23卷(第6期);第493-498页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016138735A3 (https=) | 2018-05-03 |
| JP2017512789A (ja) | 2017-05-25 |
| MY196243A (en) | 2023-03-24 |
| RU2016138735A (ru) | 2018-05-03 |
| EP3122747B1 (en) | 2020-05-20 |
| CN104945395A (zh) | 2015-09-30 |
| RU2682672C2 (ru) | 2019-03-20 |
| US20160347746A1 (en) | 2016-12-01 |
| MX2016012573A (es) | 2018-02-19 |
| US9771358B2 (en) | 2017-09-26 |
| KR20160133563A (ko) | 2016-11-22 |
| AU2015236982A1 (en) | 2016-08-11 |
| EP3122747A1 (en) | 2017-02-01 |
| SG11201605896WA (en) | 2016-08-30 |
| CA2938050A1 (en) | 2015-10-01 |
| AU2015236982B2 (en) | 2017-12-14 |
| WO2015144093A1 (en) | 2015-10-01 |
| EP3122747A4 (en) | 2017-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104945395B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN104650068B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN109678859B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN104926808B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN103664899B (zh) | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 | |
| CN104650069A (zh) | 4-甲基二氢嘧啶类化合物及其在药物中的应用 | |
| CN109111451B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN103664925A (zh) | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 | |
| CN104650070B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| KR102496508B1 (ko) | 디하이드로피리미딘 화합물 및 이러한 화합물의 제조 방법 및 용도 | |
| CN111825676A (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| WO2020221280A1 (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN110903284A (zh) | 稠合三环类化合物及其在药物中的应用 | |
| CN111303118B (zh) | 化合物及其在治疗乙型肝炎中的用途 | |
| WO2021143885A1 (zh) | 稠合四环类化合物及其在药物中的应用 | |
| HK40002930A (en) | Dihydropyrimidine compound and preparation method and use thereof | |
| HK40002930B (en) | Dihydropyrimidine compound and preparation method and use thereof | |
| HK1228400B (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1228400A1 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1224286B (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1206027B (en) | 2,4,5,6-substituted 3,6-dihydropyrimidine derivatives as hepatitis b virus (hbv) polymerase inhibitors for the treatment of e.g. chronic hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Heteroaryl-substituted dihydropyrimidine compounds and application thereof in medicines Effective date of registration: 20200514 Granted publication date: 20180123 Pledgee: Zhongrong International Trust Co.,Ltd. Pledgor: SUNSHINE LAKE PHARMA Co.,Ltd. Registration number: Y2020990000464 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220915 Granted publication date: 20180123 Pledgee: Zhongrong International Trust Co.,Ltd. Pledgor: SUNSHINE LAKE PHARMA Co.,Ltd. Registration number: Y2020990000464 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| CP03 | Change of name, title or address |
Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd. Address before: 523000 Songshan Lake Science and Technology Industrial Park, Dongguan, Guangdong (No. 1 Industrial North Road, Hubei Industrial Park, Songshan) Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd. |
|
| CP03 | Change of name, title or address |